Laureate Pharma signs development and manufacturing agreement to develop fusion protein products

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a unique Fc Fusion Protein and produce this product under cGMP conditions for use in clinical trials. Terms of the manufacturing agreement were not disclosed.

"This project is a great fit with the experience that we have developed over the past few years working with fusion proteins," said Robert J. Broeze, Ph. D., President & CEO of Laureate Pharma. "We have had great success working with these unique protein products and are delighted to have the opportunity to help advance this product into the clinic."

"We are seeing a strong trend in the biopharmaceutical industry to develop fusion protein products with unique properties," commented Dan Leone, Vice President, Business Development of Laureate Pharma. "Along with monoclonal antibodies, manufacturing fusion proteins has become one of Laureate's core competencies."